Paulson holds stake in gold steady in third-quarter
Tweet
Share
E-mailNEW YORK (Reuters) - Paulson & Co left its stake in gold investments unchanged in the third quarter, as concerns about North Korea's nuclear weapons program helped lift bullion prices to a 13-month high, a U.S. Securities and Exchange Commission filing showed on Tuesday.
Soros Fund Management LLC stayed out of gold for the fourth straight quarter.
New York-based Paulson & Co, led by longtime gold bull John Paulson, kept its stake in SPDR Gold Trust at 4.36 million shares with a value of $530 million at the end of September, up from a value of $514.5 million in the second quarter, the 13F filing showed.
SPDR Gold Trust is the world's biggest gold exchange-traded fund.
Paulson also left stakes unchanged in AngloGold Ashanti Ltd and NovaGold Resources Inc, though their value declined versus the end of the second quarter. Stakes in IAMGOLD Corp, RandGold Resources Ltd, and Seabridge Gold Inc were also unchanged but their value rose.
Spot gold prices rose 10 percent in September, from the end of the second quarter, to a 13-month high at $1,357.54 an ounce, on safe-haven buying due to rising tensions on the Korean peninsula and concerns Pyongyang might launch more missiles after conducting nuclear tests.
Weak U.S. economic data also briefly lowered expectations for an interest rate hike in December.
Bullion prices later pared gains to close the third quarter up 3 percent as expectations for the U.S. Federal Reserve to hike rates returned.
CI Investments Inc sharply increased its holdings in SPDR Gold Trust to nearly 1.45 million shares worth $176.2 million in the three-month period ended Sept. 30, up more than five times from its 267,329 shares at the end of the second quarter, filings showed last week.
(Reporting by Marcy Nicholson; Editing by Matthew Lewis and Tom Brown)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- EU panel backs NewAmsterdam and Menarini cholesterol drugs
- MannKind raises $50M in private placement led by Frazier Life Sciences
Create E-mail Alert Related Categories
13Fs, Hedge Funds, ReutersRelated Entities
Paulson & Co. (PCI), Soros Fund Management, Second Curve CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
